Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan YZY Biopharma CoHKSE:02496 EBITDA Margin % is -75.96% as of Dec. 2025. The stock has 8 warning signs investors should review. Among 940 Biotechnology companies, Wuhan YZY Biopharma Co ranks worse than 54.79% on this metric.
Wuhan YZY Biopharma Co (HKSE:02496) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wuhan YZY Biopharma Co EBITDA Margin % Related Terms
Wuhan YZY Biopharma Co EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Wuhan YZY Biopharma Co's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02496 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Wuhan YZY Biopharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan YZY Biopharma Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan YZY Biopharma Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wuhan YZY Biopharma Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan YZY Biopharma Co (HKSE:02496) has a EBITDA Margin % of -75.96% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuhan YZY Biopharma Co and its competitors. According to the industry distribution chart, Wuhan YZY Biopharma Co ranks #515 out of 940 companies in the Biotechnology industry, placing it in the top 54.8%.
Is Wuhan YZY Biopharma Co's EBITDA Margin % too high?
Wuhan YZY Biopharma Co's current EBITDA Margin % is -75.96%. Based on the distribution chart, Wuhan YZY Biopharma Co ranks #515 out of 940 companies in the Biotechnology industry, which is below the industry midpoint.
How does Wuhan YZY Biopharma Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan YZY Biopharma Co ranks #515 out of 940 companies for EBITDA Margin %. This places Wuhan YZY Biopharma Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuhan YZY Biopharma Co and its competitors. Wuhan YZY Biopharma Co's current EBITDA Margin % is -75.96%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan YZY Biopharma Co stock overvalued right now?
Wuhan YZY Biopharma Co (HKSE:02496) has a current EBITDA Margin % of -75.96%. The current EBITDA Margin % is -75.96%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wuhan YZY Biopharma Co (HKSE:02496), the current EBITDA Margin % is -75.96% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Wuhan YZY Biopharma Co Ltd is a biotechnology company dedicated to developing bispecific antibody (BsAb)- based therapies. The Company has been forward-looking in deploying its presence in several therapeutic fields, including but not limited to tumor-associated complications, tumors, ophthalmology, and autoimmune diseases. The Company also proactively established several self-developed technology platforms, such as Y-BODY, Check-Body, and Nano-Ybody, promoting the development of more candidates to clinical stages with high efficiency.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02496 has been successfully added to your 
